Italy

BMI View: The Italian pharmaceutical market continues to be a challenging proposition and BMI believes the sector will be a target of further cost containment in 2012, particularly... 2012-01-24

BMI View: Menarini's acquisition of Invida will reduce the Italian drugmaker's exposure to Italy - decreasing the company's operational risk in the face of deteriorating local industry... 2011-11-24

BMI View: The Italian pharmaceuticals and healthcare sector will be the target of further cost containment measures in 2011, as while public hospital spending has decreased, hospitals... 2011-11-18

BMI View: Italy maintains one of the largest sovereign debt loads in the world and continues to receive negative attention from bond markets. We believe the Italian government's decision... 2011-07-28

BMI view: Deficits remain a key challenge for the majority of governments across Europe. While many sectors may see only limited downside risks from the situation, the pharmaceutical... 2011-07-25

BMI View: The Italian pharmaceuticals and healthcare sector will be the target of further cost containment measures in 2011, as while public hospital spending has decreased, hospitals... 2011-06-23

BMI Core View: Governments will increasingly impose price controls on pharmaceuticals. Drugmakers have generally charged what the market will bear in both developed and emerging markets.... 2011-05-11

BMI Core View: The uptake of generic drugs following patent expiries will become swifter. This trend will reduce costs for governments, out-of-pocket payers and insurance companies,... 2011-02-16

BMI View: Innovative drugmakers will benefit from the Italian Medicines Agency (AIFA)'s focus on improving patient access to high-value therapeutics. The agency has published its first... 2011-01-06

BMI View: We welcome the Italian Medicines Agency's focus on improving patient access to high-value therapeutics - in particular oncology medicines - as it can take up to an average... 2010-10-28